NCT07228832Phase 3Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Study sponsor: Summit Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-05-31Estimated
Enrollment · participants900Estimated
Source updated2026-11-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 300 participants

Before: 600 participants (planned). After: 900 participants (planned).

Check registry source